Loading stock data…
Verrica Pharmaceuticals Inc. (VRCA)
$5.26-0.04 (-0.75%)
Market ClosedLast close Sep 8
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Verrica Pharmaceuticals Inc. in the Healthcare sector is trading at $5.26 with a market capitalization of $101M. Wall Street consensus targets $13.83 (6 analysts), implying a +163.0% move over the next 12 months. The stock is currently 46% below its 52-week high of $9.82, remaining 16.0% below its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +163.0% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $5.02M↓ | $5.09M↓ | $14.34M↑ | $12.70M↑ | $3.44M |
| Gross Profit | $4.13M↑ | $3.69M↓ | $13.23M↑ | $12.21M↑ | $3.00M |
| Operating Income | -$9.71M↓ | -$6.95M↓ | $1.63M↑ | $1.51M↑ | -$8.13M |
| Net Income | -$9.68M↓ | -$8.07M↓ | -$274,000↓ | $204,000↑ | -$9.74M |
Peer Comparison
JNJUNHPFE
Fundamentals
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combin...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$100.84M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.55
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-111.03%
Volume
Today's trading volume
112,195
Recent News
Verrica completes enrolment in Phase III trial of Ycanth
The COVE-2 trial follows a previously completed Phase II trial that had shown a decline in the number of common warts.
Verrica Pharmaceuticals Q2 Earnings Call Highlights
Verrica Pharmaceuticals (NASDAQ:VRCA) reported second-quarter revenue growth in its YCANTH treatment for molluscum contagiosum, while outlining progress in pivotal studies of the product for common warts and announcing a credit facility that management said could extend its cash runway into 2028. C
Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Beats Revenue Estimates
Verrica Pharmaceuticals (VRCA) delivered earnings and revenue surprises of +14.29% and +1.77%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Verrica Pharmaceuticals Inc. Q1 2026 Earnings Call Summary
Moby summary of Verrica Pharmaceuticals Inc.'s Q1 2026 earnings call
Transcript: Verrica Pharmaceuticals Q1 2026 Earnings Conference Call
On Tuesday, Verrica Pharmaceuticals (NASDAQ:VRCA) discussed first-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www.benzinga.com/apis/ for a consultation. Access the full call at https://viavid.webcasts.com/starthere.jsp?ei=1758586&tp_key=307852c58b Summary Verrica Pharmaceuticals Inc reported a total revenue of $5 million for Q1 2026,